Molecular therapy of primary hyperoxaluria

Area of Science:

• Biochemistry
• Genetics
• Metabolic Diseases

Background:

• Primary hyperoxalurias (PHs) are severe inherited metabolic disorders.
• Enzymatic deficits are central to PH pathogenesis.
• Cell-autonomous nature of deficiency presents therapeutic challenges.

Purpose of the Study:

• To review molecular understanding and therapeutic approaches for PHs.
• To highlight the role of preclinical studies in developing novel treatments.
• To discuss the potential of molecular therapies for PH patients.

Main Methods:

• Exploration of various molecular strategies including enzyme replacement, substrate reduction, pharmacologic chaperones, gene, and cell therapies.
• Utilizing PH mouse models for preclinical research.
• Translating proof-of-concept studies towards clinical trials.

Main Results:

• Significant progress in understanding PH molecular mechanisms.
• Successful preclinical testing of innovative therapeutic strategies in PH models.
• Advancement of some therapies into clinical trials for PH type 1.

Conclusions:

• Novel molecular therapies hold promise for treating primary hyperoxalurias.
• Preclinical research in PH models is crucial for therapeutic development.
• Clinical trials offer hope for effective treatments for this inborn error of metabolism.